VNDA
Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals Inc. (VNDA) has 15 SEC Form 4 filings (15 transaction rows) in the rolling window, disclosed by 6 distinct insiders. Most recent filing: Jun 8, 2026.
Insiders have net sold $2.8M over the trailing 6 months.
- Industry:Biotechnology
- CEO:Mihael H. Polymeropoulos
- Employees:368
- HQ:Washington, DC, US
- IPO:2006-04-12
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$2.8M
reported sales (SEC code S)
Unique Insiders
6
in the rolling window
Market Cap
$320.5M
latest known value
| Source | ||||||
|---|---|---|---|---|---|---|
Williams TimothyFirst filing | SVP & General Counsel | Sale | 42,434 | $351K | Mar 4 | SEC ↗ |
Birznieks GuntherFirst filing | SVP, Business Development | Sale | 42,431 | $351K | Mar 4 | SEC ↗ |
Polymeropoulos Mihael HristosFirst filing | President and CEO | Sale | 156,235 | $1.3M | Mar 4 | SEC ↗ |
Moran Kevin PatrickFirst filing | SVP, CFO & Treasurer | Sale | 42,442 | $351K | Mar 4 | SEC ↗ |
Wijkstrom JoakimFirst filing | SVP, Chief Marketing Officer | Sale | 30,800 | $255K | Mar 4 | SEC ↗ |
Honore TageFirst filing | Director | Sale | 30,000 | $241K | Feb 24 | SEC ↗ |
Related companies
Vanda Pharmaceuticals Inc. is in the Healthcare sector.